Selected publications from the Brunaugh Lab. For a complete list, see Google Scholar.
2026
Romero-Gonzalez M, Park M, Chen Z, Xia G, Dechayont B, Brunaugh AD. Colistin-stabilized antisolvent precipitation enables engineering of microcrystalline niclosamide for inhalable composite powders. International Journal of Pharmaceutics, 2026.
Xia G, Dechayont B, Che L, Comfort I, Brunaugh AD. A distribution-based metric for quantifying dispersibility in dry powder inhalers. Pharmaceutics, 2026.
2025
Romero-Gonzalez M, Park M, Lin W, Caverly LJ, Brunaugh AD. Physiologically informed in vitro framework reveals context-dependent combinatory activity of niclosamide–colistin against Gram-negative bacteria. Journal of Antimicrobial Chemotherapy, 80(11): 2958–2969, 2025.
2024
Romero-Gonzalez M, Crowther J, Ordoubadi M, Brunaugh AD. Strategies to overcome undesired physicochemical changes in particle engineering for inhalation. KONA Powder and Particle Journal, 2024:2025008.
2023
Warnken Z, Trementozzi A, Martins PP, Parekh J, Koleng JJ, Smyth HDC, Brunaugh A. Development of low-cost, weight-adjustable clofazimine mini-tablets for treatment of tuberculosis in pediatrics. European Journal of Pharmaceutical Sciences, 2023:106470.
2022
Brunaugh AD, Walz A, Warnken Z, Pearce C, Munoz Gutierrez J, Koleng JJ, Smyth HDC, Gonzalez-Juarrero M. Respirable clofazimine particles produced by air jet milling technique are efficacious in treatment of BALB/c mice with chronic Mycobacterium tuberculosis infection. Antimicrobial Agents and Chemotherapy, 2022:e00186-22.
Brunaugh AD, Ding L, Wu T, Schneider M, Khalaf R, Smyth HDC. Identification of stability constraints in the particle engineering of an inhaled monoclonal antibody dried powder. Journal of Pharmaceutical Sciences, 111(2): 403–416, 2022.
2021
Brunaugh AD, Sharma S, Smyth HDC. Inhaled fixed-dose combination powders for the treatment of respiratory infections. Expert Opinion on Drug Delivery, 2021:1–5.
Brunaugh AD, Seo H, Warnken Z, Ding L, Seo SH, Smyth HDC. Development and evaluation of inhalable composite niclosamide-lysozyme particles: A broad-spectrum, patient-adaptable treatment for coronavirus infections and sequalae. PLoS One, 16(2): e0246803, 2021.
2019
Brunaugh AD, Wu T, Kanapuram SR, Smyth HDC. Effect of particle formation process on characteristics and aerosol performance of respirable protein powders. Molecular Pharmaceutics, 16(10): 4165–4180, 2019.
2018
Brunaugh AD, Smyth HDC. Formulation techniques for high dose dry powders. International Journal of Pharmaceutics, 547(1–2): 489–498, 2018.
Brunaugh A, Smyth HDC. Process optimization and particle engineering of micronized drug powders via milling. Drug Delivery and Translational Research, 8(6): 1740–1750, 2018.
2017
Brunaugh AD, Jan SU, Ferrati S, Smyth HDC. Excipient-free pulmonary delivery and macrophage targeting of clofazimine via air jet micronization. Molecular Pharmaceutics, 14(11): 4019–4031, 2017.